Abingworth Appoints New Partner
This article was originally published in Scrip
Shelley Chu has joined international investment group, Abingworth, as a partner and will source and manage deals across various therapeutic areas and stages of development. Chu joins the company from Gilead Sciences where she led business development in oncology, immunotherapy and hepatitis B, as well as R&D Strategy. Previously she was principal at Frazier Healthcare Ventures.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.